The Scottish Medicines Consortium (SMC) has accepted CSL Behring’s Hemgenix (etranacogene dezaparvovec) for use within NHS Scotland on an interim basis, until full marketing authorisation is granted. The single infusion gene therapy is recommended for adults with severe or moderately severe haemophilia B without a history of FIX inhibitors. The decision follows the recommendation from […]